Benefits and harms of cervical screening, triage and treatment strategies in women living with HIV.

"Competing interests K.S. received salary support from Cancer Institute NSW (Australia, grant no. CDF1004). M.A. was supported by the Horizon 2020 Framework Program for Research and Innovation of the European Commission, through the Risk-based Screening for Cervical Cancer (RISCC) Network (grant no. 847845). K.C. receives salary support from the National Health and Medical Research Council (Australia, grant no. APP1135172). K.C. is co-principal investigator and M.C. is an investigator on an investigator-initiated trial of cytology and primary HPV screening in Australia (‘COMPASS’) (ACTRN12613001207707 and NCT02328872), which is conducted and funded by the Australian Centre for the Prevention of Cervical Cancer, a government-funded health promotion charity. The Australian Centre for the Prevention of Cervical Cancer has received equipment and a funding contribution for the COMPASS trial from Roche Molecular Systems and operational support from the Australian Government. K.C. is also co-principal investigator on a major implementation program, ‘Elimination of Cervical Cancer in the Western Pacific’, which receives support from the Minderoo Foundation and equipment donations from Cepheid, Inc. All declared funders had no role in the study design, in the collection, analysis and interpretation of data, in the writing of the report or in the decision to submit the manuscript for publication."

"We acknowledge the contribution of the WHO Guidelines Development Group for Screening and Treatment to Prevent Cervical Cancer, which helped formulate inputs to the modeled evaluation and provided critical feedback on our results. The development of the Guidelines Development Group was done in accordance with the WHO’s Handbook for Guideline Development (https://www.who.int/publications/i/item/9789241548960), which includes a requirement for representation from all WHO regions that will be impacted by the guidelines. The Guidelines Development Group included scientists, healthcare providers, implementers, ministry of health representatives, systematic reviewers, program implementation experts, survivors and representatives from special interest groups and civil society and also included members from all five WHO regions (AFRO, SEARO, WPRO, EURO and EMRO), many from LMICs. The names of group members are listed in the annex of the WHO guidelines (https://www.who.int/publications/i/item/9789240030824). Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article, and they do not necessarily represent the decisions, policies or views of the International Agency for Research on Cancer/World Health Organization. This work was funded by UNDP/UNFPA/UNICEF/WHO/World Bank Special Program of Research, Development and Research Training in Human Reproduction (HRP/World Health Organization). Competing interests: K.S. received salary support from Cancer Institute NSW (Australia, grant no. CDF1004). M.A. was supported by the Horizon 2020 Framework Program for Research and Innovation of the European Commission, through the Risk-based Screening for Cervical Cancer (RISCC) Network (grant no. 847845). K.C. receives salary support from the National Health and Medical Research Council (Australia, grant no. APP1135172). K.C. is co-principal investigator and M.C. is an investigator on an investigator-initiated trial of cytology and primary HPV screening in Australia (‘COMPASS’) (ACTRN12613001207707 and NCT02328872), which is conducted and funded by the Australian Centre for the Prevention of Cervical Cancer, a government-funded health promotion charity. The Australian Centre for the Prevention of Cervical Cancer has received equipment and a funding contribution for the COMPASS trial from Roche Molecular Systems and operational support from the Australian Government. K.C. is also co-principal investigator on a major implementation program, ‘Elimination of Cervical Cancer in the Western Pacific’, which receives support from the Minderoo Foundation and equipment donations from Cepheid, Inc. All declared funders had no role in the study design, in the collection, analysis and interpretation of data, in the writing of the report or in the decision to submit the manuscript for publication."